KR930000511A - 결정질 옥사티올란 유도체 - Google Patents
결정질 옥사티올란 유도체 Download PDFInfo
- Publication number
- KR930000511A KR930000511A KR1019920009537A KR920009537A KR930000511A KR 930000511 A KR930000511 A KR 930000511A KR 1019920009537 A KR1019920009537 A KR 1019920009537A KR 920009537 A KR920009537 A KR 920009537A KR 930000511 A KR930000511 A KR 930000511A
- Authority
- KR
- South Korea
- Prior art keywords
- crystalline form
- hydroxymethyl
- cis
- amino
- oxathiolan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Secondary Cells (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 침상 결정 형태(형태 Ⅰ)의 3TC를 나타내는 도면.
제2도는 양추형 결정 형태(형태Ⅱ)의 3TC를 나타내는 도면.
제3도는 결정 형태 Ⅰ의 적외선 스펙트럼을 나타내는 도면.
Claims (25)
- 결정질 형태의 (-)-시스-4-아미노-1-(2-히드록시메틸-1,3-옥사티올란-5일)-(1H)-피리미딘-2-온.
- 양추형 결정 형태의 (-)-시스-4-아미노-1-(2-히드록시메틸-1,3-옥사티올란-5일)-(1H)-피리미딘-2-온.
- 제1항 또는 제2항에 있어서, 융점이 170℃이상인 결정질 형태.
- 제1항 내지 3항중 어느 한 항에 있어서, 융점이 177 내지 178℃인 결정질 형태.
- 제1항 내지 4항중 어느 한 항에 있어서, 적외선 스펙트럼의 920및 850파수에서 흡수띠를 갖는 결정질 형태.
- 제1항 내지 5항중 어느 한 항에 있어서, 적외선 스펙트럼의 1110파수에서 흡수띠가 없는 결정질 형태.
- 제1항 내지 6항중 어느 한 항에 있어서, 시차 주사 열량계 프로파일에서 177 내지 178℃에서 흡열이 개시되는 결정질 형태.
- 침상 결정 형태의 (-)-시스-4-아미노-1-(2-히드록시메틸-1,3-옥사티올란-5일)-(1H)-피리미딘-2-온.
- 제1항 또는 8항에 있어서, 융점이 약 130℃미만인 결정질 형태.
- 제1항, 8항 또는 9항에 있어서, 융점이 124 내지 127℃인 결정질 형태.
- 제1항 및 8항 내지 11항중 어느 한 항에 있어서, 시차 주사 열량계 프로파일에서 124 내지 127℃에서 흡열이 개시되는 결정질 형태.
- 제1항 및 8항 내지 11항중 어느 한 항에 있어서, 적외선 스펙트럼의 약1110파수에서 흡수띠를 갖는 결정질 형태.
- 제1도에 나타낸 결정질 형태의 (-)-시스-4-아미노-1-(2-히드록시메틸-1,3-옥사티올란-5일)-(1H)-피리미딘-2-온.
- 제2도에 나타낸 결정질 형태의 (-)-시스-4-아미노-1-(2-히드록시메틸-1,3-옥사티올란-5일)-(1H)-피리미딘-2-온.
- 제3도에 나타낸 적외선 스펙트럼을 갖는 결정질 형태의 (-)-시스-4-아미노-1-(2-히드록시메틸-1,3-옥시티올란-5일)-(1H)-피리미딘-2-온.
- 제4도에 나타낸 적외선 스펙트럼을 갖는 결정질 형태의 (-)-시스-4-아미노-1-(2-히드록시메틸-1,3-옥사티올란-5일)-(1H)-피리미딘-2-온.
- 수용액으로부터 화합물을 결정화시키는 것으로 이루어진, 결정질 형태의 (-)-시스-4-아미노-1-(2-히드록시메틸-1,3-옥사티올란-5일)-(1H)-피리미딘-2-온의 제조방법.
- 화합물의 수용액을 프로판-1-올과 함께 공비중류시키는 것으로 이루어진, 결정질 형태의 (-)-시스-4-아미노-1-(2-히드록시메틸-1,3-옥사티올란-5일)-(1H)-피리미딘-2-온의 제조방법.
- 비수성 매질로부터 재결정화시키는 것으로 이루어진, 결정질 형태의 (-)-시스-4-아미노-1-(2-히드록시메틸-1,3-옥사티올란-5일)-(1H)-피리미딘-2-온의 제조방법.
- 제19항에 있어서, 비수성 매질이 C2-6알콜인 방법.
- 제20항 또는 21항에 있어서, 비수성 매질이 에탄올 및 공업용 메틸화 주정으로부터 선택되는 방법.
- 침상 결정 형태의 화합물을 에탄올 또는 공업용 메틸화 주정 중에서 승온에서 숙성시키는 것으로 이루어진, 양추형 결정 형태의 (-)-시스-4-아미노-1-(2-히드록시메틸-1,3-옥사티올란-5일)-(1H)-피리미딘-2-온의 제조방법.
- 결정질 형태의 (-)-시스-4-아미노-1-(2-히드록시메틸-1,3-옥사티올란-5일)-(1H)-피리미딘-2-온 및 그의 제약상 허용되는 담체로 이루어진 약제.
- 제23항에 있어서, 경구 투어용으로 적절한 형태의 약제.
- 제23항 또는 24항에 있어서, 정제 또는 캡슐제 형태의 약제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9111902.4 | 1991-06-03 | ||
GB919111902A GB9111902D0 (en) | 1991-06-03 | 1991-06-03 | Chemical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
KR930000511A true KR930000511A (ko) | 1993-01-15 |
KR100244008B1 KR100244008B1 (ko) | 2000-03-02 |
Family
ID=10696001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920009537A KR100244008B1 (ko) | 1991-06-03 | 1992-06-02 | 결정질 옥사티올란 유도체 |
Country Status (31)
Country | Link |
---|---|
US (1) | US5905082A (ko) |
EP (2) | EP1099700A1 (ko) |
JP (1) | JP2851480B2 (ko) |
KR (1) | KR100244008B1 (ko) |
AP (1) | AP300A (ko) |
AT (1) | ATE212630T1 (ko) |
AU (2) | AU656379B2 (ko) |
BG (1) | BG60914B1 (ko) |
CA (2) | CA2311988C (ko) |
CZ (1) | CZ284513B6 (ko) |
DE (1) | DE69232387T2 (ko) |
DK (1) | DK0517145T3 (ko) |
ES (1) | ES2171158T3 (ko) |
GB (1) | GB9111902D0 (ko) |
GE (1) | GEP19991834B (ko) |
HK (1) | HK1009599A1 (ko) |
IE (2) | IE921780A1 (ko) |
IL (1) | IL102073A (ko) |
IS (2) | IS1867B (ko) |
MX (1) | MX9202619A (ko) |
NO (1) | NO301713B1 (ko) |
NZ (1) | NZ242981A (ko) |
OA (1) | OA09913A (ko) |
PT (1) | PT517145E (ko) |
RU (1) | RU2102393C1 (ko) |
SG (1) | SG52455A1 (ko) |
SK (1) | SK281249B6 (ko) |
TW (1) | TW254939B (ko) |
UA (1) | UA41265C2 (ko) |
WO (1) | WO1992021676A1 (ko) |
ZA (1) | ZA924007B (ko) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4581979A (en) * | 1983-07-01 | 1986-04-15 | Automotive Products Plc | Shipping and installation restraining clip for master cylinder input member |
US6069252A (en) | 1990-02-01 | 2000-05-30 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers |
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
US6812233B1 (en) | 1991-03-06 | 2004-11-02 | Emory University | Therapeutic nucleosides |
US5817667A (en) * | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
US6177435B1 (en) | 1992-05-13 | 2001-01-23 | Glaxo Wellcome Inc. | Therapeutic combinations |
US20020120130A1 (en) | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
IL115156A (en) | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
AU722214B2 (en) | 1995-06-07 | 2000-07-27 | Centre National De La Recherche Scientifique (Cnrs) | Nucleosides with anti-hepatitis B virus activity |
US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
HUP9903249A3 (en) | 1996-06-25 | 2001-04-28 | Glaxo Group Ltd | Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv |
US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
US6436948B1 (en) | 2000-03-03 | 2002-08-20 | University Of Georgia Research Foundation Inc. | Method for the treatment of psoriasis and genital warts |
AU2002335489B2 (en) * | 2001-03-01 | 2008-06-05 | Abbott Laboratories | Polymorphic and other crystalline forms of cis-FTC |
CA2351049C (en) | 2001-06-18 | 2007-03-13 | Brantford Chemicals Inc. | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers |
WO2003027106A1 (en) * | 2001-09-25 | 2003-04-03 | Cadila Healthcar Limited | Process for the preparation of crystalline polymorph ii of lamivudine |
AU2003217676B2 (en) | 2002-02-22 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Active agent delivery systems and methods for protecting and administering active agents |
ES2286471T3 (es) * | 2002-11-08 | 2007-12-01 | Glaxo Group Limited | Composiciones farmaceuticas antivirales. |
US20040224917A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
EP1809662B1 (en) * | 2004-11-10 | 2008-11-26 | Novartis Vaccines and Diagnostics, Inc. | Deamidated interferon-beta |
US20060242012A1 (en) * | 2005-04-22 | 2006-10-26 | Sumit Agarwal | Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
DE602007009957D1 (de) * | 2006-04-18 | 2010-12-02 | Lupin Ltd | Neue kristalline form von lamivudin |
WO2009031026A2 (en) * | 2007-09-06 | 2009-03-12 | Combino Pharm, S.L. | Novel pharmaceutical compositions |
WO2009037538A2 (en) * | 2007-09-17 | 2009-03-26 | Aurobindo Pharma Ltd | Process for the preparation of lamivudine form i |
US20100324290A1 (en) * | 2007-11-29 | 2010-12-23 | Ranbaxy Laboratories Limited | Crystalline form i of lamivudine and its preparation |
CN101918416A (zh) * | 2007-11-29 | 2010-12-15 | 兰贝克赛实验室有限公司 | 制备取代的1,3-氧硫杂环戊烷,尤其是拉米夫定的方法和中间体 |
EP2225232B1 (en) * | 2007-11-29 | 2012-09-26 | Ranbaxy Laboratories Limited | Process for the preparation of substituted 1,3-oxathiolanes |
WO2009127996A1 (en) * | 2008-04-17 | 2009-10-22 | Ranbaxy Laboratories Limited | Novel crystalline form of lamivudine |
US8536151B2 (en) * | 2008-09-01 | 2013-09-17 | Hetero Research Foundation | Process for preparing lamivudine polymorph form |
US20110288298A1 (en) * | 2008-11-12 | 2011-11-24 | Lupin Limited | novel polymorph of emtricitabine and a process for preparing of the same |
CN101531656B (zh) * | 2009-03-24 | 2010-12-08 | 福建广生堂药业有限公司 | 拉米夫定晶型及其制备方法 |
CN101993439B (zh) * | 2009-03-24 | 2013-04-24 | 福建广生堂药业股份有限公司 | 拉米夫定晶型及其制备方法 |
WO2010137027A1 (en) * | 2009-05-27 | 2010-12-02 | Hetero Research Foundation | Solid oral dosage forms of lamivudine |
EP2454244B1 (en) | 2009-07-15 | 2013-06-26 | Lupin Limited | An improved process for preparation of efavirenz |
EP2488516B1 (en) | 2009-10-14 | 2015-04-01 | Mylan Laboratories Limited | Process for the preparation of lamivudine and novel salts in the manufacture thereof |
ES2688925T3 (es) | 2010-01-27 | 2018-11-07 | Viiv Healthcare Company | Tratamiento antiviral |
US20120295930A1 (en) * | 2010-02-03 | 2012-11-22 | Shankar Rama | Novel process for the preparation of cis-nucleoside derivative |
AU2011215878A1 (en) * | 2010-02-12 | 2012-08-09 | Merck Sharp & Dohme Corp. | Preparation of lamivudine Form I |
CN114010776A (zh) | 2010-06-09 | 2022-02-08 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
US20130296562A1 (en) | 2011-08-05 | 2013-11-07 | Lupin Limited | Stereoselective process for preparation of 1,3-oxathiolane nucleosides |
WO2013168066A1 (en) | 2012-05-05 | 2013-11-14 | Lupin Limited | An improved process for the manufacture of lamivudine form i. |
CN114099454B (zh) * | 2020-08-31 | 2023-06-27 | 长春海悦药业股份有限公司 | 一种拉米夫定片及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
US5179104A (en) * | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
US5248776A (en) * | 1990-12-05 | 1993-09-28 | University Of Georgia Research Foundation, Inc. | Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides |
-
1991
- 1991-06-03 GB GB919111902A patent/GB9111902D0/en active Pending
-
1992
- 1992-02-06 UA UA93004068A patent/UA41265C2/uk unknown
- 1992-06-02 PT PT92109221T patent/PT517145E/pt unknown
- 1992-06-02 JP JP4166809A patent/JP2851480B2/ja not_active Expired - Lifetime
- 1992-06-02 RU RU93058495A patent/RU2102393C1/ru active
- 1992-06-02 ZA ZA924007A patent/ZA924007B/xx unknown
- 1992-06-02 NZ NZ242981A patent/NZ242981A/en not_active IP Right Cessation
- 1992-06-02 CA CA002311988A patent/CA2311988C/en not_active Expired - Lifetime
- 1992-06-02 EP EP01200491A patent/EP1099700A1/en not_active Withdrawn
- 1992-06-02 WO PCT/EP1992/001213 patent/WO1992021676A1/en active IP Right Grant
- 1992-06-02 DE DE69232387T patent/DE69232387T2/de not_active Expired - Lifetime
- 1992-06-02 NO NO922182A patent/NO301713B1/no not_active IP Right Cessation
- 1992-06-02 AT AT92109221T patent/ATE212630T1/de active
- 1992-06-02 TW TW081104300A patent/TW254939B/zh not_active IP Right Cessation
- 1992-06-02 AU AU17361/92A patent/AU656379B2/en not_active Expired
- 1992-06-02 SG SG1996004763A patent/SG52455A1/en unknown
- 1992-06-02 ES ES92109221T patent/ES2171158T3/es not_active Expired - Lifetime
- 1992-06-02 AU AU18810/92A patent/AU1881092A/en not_active Abandoned
- 1992-06-02 DK DK92109221T patent/DK0517145T3/da active
- 1992-06-02 AP APAP/P/1992/000395A patent/AP300A/en active
- 1992-06-02 GE GEAP19922654A patent/GEP19991834B/en unknown
- 1992-06-02 IS IS3873A patent/IS1867B/is unknown
- 1992-06-02 EP EP92109221A patent/EP0517145B1/en not_active Expired - Lifetime
- 1992-06-02 SK SK1257-93A patent/SK281249B6/sk not_active IP Right Cessation
- 1992-06-02 IL IL10207392A patent/IL102073A/en not_active IP Right Cessation
- 1992-06-02 US US07/892,029 patent/US5905082A/en not_active Expired - Lifetime
- 1992-06-02 CZ CS932612A patent/CZ284513B6/cs not_active IP Right Cessation
- 1992-06-02 CA CA002070230A patent/CA2070230C/en not_active Expired - Lifetime
- 1992-06-02 KR KR1019920009537A patent/KR100244008B1/ko not_active IP Right Cessation
- 1992-06-02 MX MX9202619A patent/MX9202619A/es active IP Right Grant
- 1992-07-01 IE IE178092A patent/IE921780A1/en not_active IP Right Cessation
- 1992-07-01 IE IE20020782A patent/IE20020782A1/en not_active IP Right Cessation
- 1992-12-04 IS IS4268A patent/IS4268A/is unknown
-
1993
- 1993-11-15 OA OA60437A patent/OA09913A/en unknown
- 1993-11-30 BG BG98254A patent/BG60914B1/bg unknown
-
1998
- 1998-08-31 HK HK98110312A patent/HK1009599A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930000511A (ko) | 결정질 옥사티올란 유도체 | |
RU93058495A (ru) | Кристаллические производные оксатиолана, способ их получения, фармацевтическая композиция на их основе | |
NO874966L (no) | Fremgangsmaate til fremstilling av nye katekolderivater med farmakologisk virkning. | |
SE7613959L (sv) | Antibiotisk komposition och forfarande for framstellning derav | |
KR830007841A (ko) | 무수결정 말티톨을 함유하는 함밀결정의 제조방법 | |
CY1108964T1 (el) | Πολυμορφοι τυποι ριφαξιμινης ως αντιβιοτικα | |
RU93058362A (ru) | Способы диастереоселективного синтеза нуклеозидов, промежуточные соединения, способы получения промежуточных соединений | |
MX9201637A (es) | Derivados de tiazolidindiona, proceso para su produccion y composicion farmaceutica que los contiene. | |
DE69209576D1 (de) | Pyridinderivate, deren Herstellung und Anwendung | |
ATE5854T1 (de) | Zusammensetzungen zur verwendung bei der verminderung des appetites auf kohlenhydratkalorien. | |
FI923188A (fi) | Nytt kristalliseringsfoerfarande foer steroidalt organiskt aemne och sao erhaollna foereningar. | |
AU564577B2 (en) | S-adenosylmethionine derivatives | |
KR910021394A (ko) | 카르복실산 유도체 | |
IT7831188A0 (it) | Derivati di anilina 3-sostituiti eprocedimento per la loro produzione. | |
SE7900028L (sv) | 4"-deoxi-4"acylamido-derivat av oleandemycin, erytromycin och erytromycinkarbonat jemte sett for deras framstellning och farmaceutiska beredningar innehallande sadana derivat | |
FI864970A0 (fi) | Nya kristallina salter av aryloxi-propanolaminer, foerfarande foer deras framstaellning och deras anvaendning. | |
IT8822714A0 (it) | Derivati di alcool n eterociclico. | |
JPS5411954A (en) | Starch suger composition and its production | |
NO972582L (no) | Anvendelse av teofyllinderivater, for behandling og profylakse av sjokktilstander, nye xantanforbindelser og deres fremstilling | |
ES8606378A1 (es) | Un metodo para preparar un cianoimidazol-nucleosido | |
DK313587D0 (da) | Tetrahydrobenzothiazolforbindelser, deres fremstilling og anvendelse | |
IT8024151A0 (it) | Derivati di 10-alo-e-omoeburnano eprocedimento per la loro preparazione. | |
JPS5419969A (en) | Proline derivative and its preparation | |
NO154012C (no) | Nye benzisotiazolderivater, soetningsmiddelpreparater inneholdende dem og anvendelse av forbindelsene som soetningsmidler. | |
DK0484372T3 (da) | Anvendelse af sebacinsyre og derivater deraf til fremstilling af farmaceutiske præparater til enteral og parenteral ernæring |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20111028 Year of fee payment: 13 |
|
EXPY | Expiration of term |